The $236 Billion Patent Cliff: Why Biopharma M&A Is Entering a Supercycle

Introduction

The biopharma industry is facing the largest patent cliff in its history. A ZS Associates estimate, reported by BioSpace, put roughly $236 billion in branded drug sales at risk between 2022 and 2030 as more than 190 drugs, 69 of them blockbusters, lose patent protection or regulatory exclusivity. That wave is now breaking: Humira and Stelara have already lost US exclusivity, Eliquis loses it in Europe in 2026 and in the US in 2028, and Keytruda follows from late 2028. This is not a gradual erosion but a concentrated wave of loss-of-exclusivity (LOE) events hitting the industry's most profitable products within a compressed window, and it has pushed every major pharma company into an M&A posture that ranges from selective to urgent. The result is a structural M&A supercycle: EY's Firepower report counted roughly $240 billion of life sciences M&A signed in 2025, up 81% on 2024, and 2026 is running well ahead of that pace.

The concentration of revenue at risk is unprecedented. Several individual products facing LOE are franchises so large that no single pipeline program can replace them, and the companies that own them are among the most active acquirers in the market.

Two features of this table matter more than the headline total. The first is single-product dependence: Keytruda and Keytruda Qlex produced $31.7 billion in 2025, nearly half of Merck's sales, according to Merck's full-year 2025 results. The second is modality. Eliquis is a small molecule, so generic entry strips most of its revenue quickly; GlobalData's analysis in Pharmaceutical Technology expects the impact of US expiry in 2028 to be immediate and severe. Keytruda, Dupixent and Stelara are biologics, where biosimilar competition erodes revenue more slowly but still decisively, as J&J found when Stelara biosimilars pulled its 2025 immunology sales down by almost 12%.

Patent Cliff

A concentrated period in which multiple blockbuster drugs lose patent protection or regulatory exclusivity, enabling generic or biosimilar competition that typically erodes 80-90% of branded revenue for small molecules within 12-18 months, and 30-50% for biologics within 3-5 years of biosimilar entry. The current patent cliff is historically large because the "golden era" of drug development (2010-2020) produced numerous blockbusters with overlapping patent expiration timelines.

The cliff also compounds with policy. Eliquis was among the first ten drugs selected for Medicare price negotiation, and its negotiated price took effect in January 2026, two years before generic entry. The Inflation Reduction Act therefore shortens the peak-revenue window for the largest small molecules even before patents expire, which adds to the pressure to buy replacement revenue rather than wait for it.

The math is brutally simple. A company facing $15 billion in revenue losses over the next four to five years needs to replace that revenue to hold its earnings trajectory and share price. Internal R&D, even at the most productive companies, takes 10-15 years from target identification to approved drug. That timeline is incompatible with a cliff arriving in two to four years, so acquisition is the only mechanism that can deliver revenue on the required timeline.

The build-vs-buy analysis extends beyond timeline. Only about 7.9% of drugs entering Phase I reached approval on 2011-2020 data (see probability of success by phase), so a company needs roughly 12-13 Phase I starts to produce one approved drug. Once failures and the cost of capital are included, a JAMA study of 63 FDA-approved drugs estimated a median capitalized R&D cost of about $1.1 billion per new medicine, rising to about $2.8 billion for cancer drugs. Acquiring a Phase III asset, even at a significant premium, can be cheaper per unit of expected revenue than internal development, particularly when the deal also brings near-term revenue from approved products and removes most of the clinical risk.

Lifecycle Management: The Third Option

Buying is not the only response. Owners of mega-blockbusters also defend the franchise itself through lifecycle management. Merck's subcutaneous Keytruda Qlex, approved in September 2025, carries its own patents beyond the IV product's 2028 expiry, and Sanofi has promised a vigorous defense of Dupixent through formulation patents that could extend protection past 2031. These tactics slow the erosion curve but rarely replace the lost revenue, which is why Merck, the company with the most to lose, has been among the most active buyers.

The patent cliff urgency has produced a measurable supercycle in biopharma M&A. EY's 2025 total came with average deal size up 107%, as buyers concentrated capital on assets at or near launch. On IQVIA's narrower biopharma count, the first half of 2026 alone produced $130 billion across 42 deals, almost matching its $133 billion total for all of 2025. The mega-deals of 2024-2026 are overwhelmingly driven by patent cliff dynamics.

M&A Supercycle

A period of structurally elevated M&A activity driven by industry-wide forces (rather than individual company decisions) that sustain above-average deal volumes for multiple years. The current biopharma supercycle is driven by the convergence of the $236 billion patent cliff, biotech valuations that sat well below their 2021 peak when the cycle began (making targets cheaper), strong pharma balance sheets (from recent blockbuster revenue), and the GLP-1 revolution creating a market that most sell-side forecasts put at roughly $100 billion by 2030. Supercycles differ from normal M&A peaks because the underlying drivers are structural and multi-year, not cyclical or sentiment-driven.

Merck: Urgency With a Walk-Away Point

Merck shows both the urgency and its limits. With Keytruda generating $31.7 billion and its main US compound patent expiring in December 2028, Merck agreed in 2025 to buy Verona Pharma (about $10 billion) and Cidara Therapeutics ($9.2 billion), pushing beyond oncology into respiratory and infectious disease. In January 2026 it held talks to acquire Revolution Medicines, whose RAS(ON) inhibitors target among the most common oncogenic drivers, for a reported $28-32 billion, which would have been the largest biopharma deal since Pfizer/Seagen. Merck ended the talks when the two sides could not agree on price, then agreed in March 2026 to buy Terns Pharmaceuticals for $6.7 billion, a 31% premium to the 60-day average price, for an oral leukemia drug. The lesson: urgency raises the price a buyer will pay, but it does not remove the walk-away point.

Across the market, 2026 has favored bolt-ons in the $5-11 billion range over transformational mergers. AbbVie/Apogee ($10.9 billion), GSK/Nuvalent ($10.6 billion), Gilead/Arcellx ($7.8 billion) and Lilly/Centessa ($7.8 billion) mostly target late-stage or near-commercial assets, and buyers have preferred several of these deals to another Seagen-sized bet.

The patent cliff supercycle creates opportunities across the healthcare banking ecosystem. Sell-side mandates for clinical-stage biotechs are commanding higher fees as deal values increase, and competitive tension is common: Pfizer won Metsera in November 2025 only after a bidding war with Novo Nordisk. Buy-side advisory for pharma companies evaluating targets requires sophisticated pipeline valuation and rNPV analysis. Earnout and milestone structuring is increasingly complex as deals use contingent consideration to bridge valuation gaps on clinical-stage assets. The Metsera deal is a clean example: $65.60 per share in cash plus a contingent value right worth up to $20.65 per share, payable only if three clinical and regulatory milestones are met.

The next article examines the Inflation Reduction Act and its impact on healthcare dealmaking, including how Medicare drug price negotiation is reshaping pharma portfolio strategy.